Sanofi updates financials to exclude Opella division, focusing more on biopharma.
Sanofi has updated its financial statements to exclude its Opella consumer healthcare division, as the company plans to transfer a 50% stake to CD&R. The revised data, reviewed by auditors, includes sales and business net income, and will be listed as discontinued operations. Sanofi is aiming to focus more on biopharma. The company's Q4 2024 results, reflecting the new scope, will be released on January 30, 2025.
4 months ago
5 Articles
Further Reading
You have 12 free stories remaining this month. Subscribe anytime for unlimited access.